A siRNA developed for the treatment of primary hyperoxaluria was designed to target the hydroxyacid oxidase 1 gene (HAO1) [69], which encodes glycolate oxidase, a key enzyme in oxalate synthesis. The gene discussed is HAO1; the disease is primary hyperoxaluria.